We create innovative treatments for nervous system damage due to injury or disease.
NervGen Pharma
NervGen (TSX-V: NGEN, OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic injury and disease. Our lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial in the company’s initial target indication, spinal cord injury. NervGen has initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury.
Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury
NervGen is actively recruiting for a landmark Phase 1b/2a proof-of-concept clinical trial of
NVG-291 in individuals with spinal cord injury.
For information regarding recruitment, the call center phone number is +1 (855) 559-6902.
View our Corporate Presentation
Stay Connected
Subscribe to our mailing list to stay up to date
The Latest
News Release
February 6, 2025
NervGen announced the first subject has been enrolled and dosed in the subacute cohort of its Phase 1b/2a clinical trial evaluating NVG-291 in individuals with SCI.
News Release
January 2, 2025
NervGen announced enrollment of the 20th and final subject in the chronic cohort of its Phase 1b/2a clinical trial evaluating NVG-291 in individuals with SCI.
NEWS RELEASE
November 14, 2024
NervGen reported its financial and operational results for the third quarter ended September 30, 2024.
